Replies to post #235500 on Biotech Values

[dewophile]

Ascribing negative value to a biotech pipeline is nothing new or uncommon, as you know. (Wasn’t there a table of biotechs trading below cash at one time). It’s not hard to waste money in drug development. What is surprising though is a company like ENTA not getting any benefit of the doubt in light of their track record.

[jbog]

In other words, investors are currently ascribing negative value to ENTA’s RSV, HBV, and NASH pipeline!

I exited over a year ago ENTA for just that reason.